Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.58)
# 827
Out of 5,124 analysts
13
Total ratings
81.82%
Success rate
19.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $32.76 | +95.36% | 2 | Dec 1, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Hold | n/a | $8.99 | - | 2 | Nov 11, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $41.14 | +11.81% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $18.71 | +28.27% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $5.92 | +356.08% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $4.30 | +806.98% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $16.15 | +85.76% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $11.43 | +101.22% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $27.75 | +65.77% | 1 | Sep 19, 2024 |
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $32.76
Upside: +95.36%
Intellia Therapeutics
Nov 11, 2025
Downgrades: Hold
Price Target: n/a
Current: $8.99
Upside: -
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $41.14
Upside: +11.81%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $18.71
Upside: +28.27%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $5.92
Upside: +356.08%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $4.30
Upside: +806.98%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $16.15
Upside: +85.76%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $11.43
Upside: +101.22%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $27.75
Upside: +65.77%